Outlook Therapeutics Stock Climbs 38% After Winning FDA Appeal For NAMD Therapy

Outlook Therapeutics shares surged about 38% after the U.S. FDA granted its appeal following the Formal Dispute Resolution process for ONS-5010/LYTENAVA, its investigational ophthalmic drug. The decision is a significant regulatory win for the company and materially improves the drug's path forward, making the news highly stock-specific and positive for sentiment.

Analysis

Outlook Therapeutics shares surged about 38% after the U.S. FDA granted its appeal following the Formal Dispute Resolution process for ONS-5010/LYTENAVA, its investigational ophthalmic drug. The decision is a significant regulatory win for the company and materially improves the drug's path forward, making the news highly stock-specific and positive for sentiment.